Privi Speciality Chemicals Ltd
Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. [1]
- Market Cap ₹ 14,129 Cr.
- Current Price ₹ 3,617
- High / Low ₹ 3,785 / 2,173
- Stock P/E 40.4
- Book Value ₹ 361
- Dividend Yield 0.28 %
- ROCE 22.3 %
- ROE 26.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 26.8% CAGR over last 5 years
Cons
- Stock is trading at 10.0 times its book value
- Promoter holding has decreased over last 3 years: -13.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 597 | 1,024 | 1,341 | 1,631 | 1,277 | 1,404 | 1,608 | 1,752 | 2,101 | 2,564 | 2,671 | |
| 525 | 894 | 1,128 | 1,362 | 1,067 | 1,209 | 1,420 | 1,423 | 1,643 | 1,912 | 2,005 | |
| Operating Profit | 72 | 130 | 213 | 268 | 210 | 195 | 188 | 329 | 458 | 651 | 666 |
| OPM % | 12% | 13% | 16% | 16% | 16% | 14% | 12% | 19% | 22% | 25% | 25% |
| 10 | 16 | 14 | 66 | 43 | 38 | 21 | 26 | 20 | 19 | 26 | |
| Interest | 20 | 24 | 29 | 41 | 24 | 25 | 70 | 102 | 92 | 87 | 75 |
| Depreciation | 27 | 43 | 47 | 63 | 71 | 75 | 108 | 123 | 132 | 144 | 145 |
| Profit before tax | 36 | 79 | 152 | 231 | 158 | 133 | 31 | 130 | 255 | 440 | 472 |
| Tax % | 24% | 32% | 38% | 24% | 26% | 27% | 31% | 27% | 27% | 28% | |
| 27 | 53 | 94 | 176 | 117 | 97 | 21 | 95 | 185 | 317 | 342 | |
| EPS in Rs | 7.21 | 14.19 | 24.10 | 45.10 | 29.90 | 24.91 | 5.68 | 24.27 | 47.83 | 83.77 | 89.47 |
| Dividend Payout % | 14% | 11% | 10% | 3% | 7% | 8% | 0% | 8% | 10% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 144% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 15% |
| 3 Years: | 50% |
| 1 Year: | 47% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 19% |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 406 | 451 | 537 | 702 | 683 | 773 | 790 | 885 | 1,064 | 1,373 |
| 321 | 330 | 491 | 569 | 537 | 933 | 1,079 | 1,008 | 1,143 | 1,021 | |
| 174 | 235 | 359 | 294 | 281 | 431 | 483 | 410 | 544 | 736 | |
| Total Liabilities | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
| 388 | 437 | 498 | 725 | 598 | 704 | 1,017 | 1,034 | 1,156 | 1,169 | |
| CWIP | 24 | 49 | 95 | 40 | 175 | 373 | 100 | 99 | 141 | 314 |
| Investments | 1 | 3 | 0 | 1 | 0 | 12 | 7 | 40 | 8 | 54 |
| 527 | 564 | 833 | 839 | 768 | 1,087 | 1,268 | 1,169 | 1,485 | 1,633 | |
| Total Assets | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 107 | 21 | 247 | 172 | 5 | 49 | 354 | 281 | 550 | |
| 80 | -81 | -139 | -206 | -242 | -321 | -133 | -180 | -294 | -358 | |
| -89 | -20 | 122 | 27 | 0 | 333 | 72 | -171 | 39 | -198 | |
| Net Cash Flow | 7 | 5 | 4 | 68 | -69 | 17 | -12 | 4 | 26 | -6 |
| Free Cash Flow | 17 | 107 | 46 | 37 | -71 | -304 | -91 | 212 | -17 | 230 |
| CFO/OP | 49% | 96% | 24% | 120% | 101% | 19% | 33% | 116% | 77% | 102% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 82 | 90 | 60 | 68 | 69 | 67 | 72 | 68 | 75 |
| Inventory Days | 236 | 132 | 162 | 135 | 170 | 279 | 311 | 245 | 262 | 235 |
| Days Payable | 115 | 85 | 95 | 55 | 83 | 138 | 114 | 105 | 134 | 150 |
| Cash Conversion Cycle | 227 | 129 | 157 | 139 | 155 | 209 | 264 | 212 | 197 | 160 |
| Working Capital Days | 31 | 20 | 40 | 45 | 65 | 19 | 16 | 37 | 35 | 54 |
| ROCE % | 13% | 18% | 20% | 12% | 10% | 6% | 12% | 16% | 22% |
Insights
In beta| Jul 2016 | Jul 2017 | Sep 2020 | Jan 2022 | Mar 2023 | Jul 2024 | May 2026 | |
|---|---|---|---|---|---|---|---|
| Sales Volume MT |
|
||||||
| Number of Manufacturing Facilities count |
|||||||
| CST Processing Capacity MTPA |
|||||||
| Number of Countries Exported To count |
|||||||
| Number of Products count |
|||||||
| Total Production Capacity MTPA |
|||||||
| R&D Team Strength count |
|||||||
| Number of Distribution Centres count |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Audio recording of analyst/investor call on Q1 FY2026-27 results, held July 31, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Investors Presentation - Financial and Operation Review for quarter ended June 30,2026.
-
Unaudited Financial Results For The Quarter Ended June 30,2026.
2d - Q1 FY27 standalone and consolidated results approved on July 30, 2026; limited review unmodified.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E Thursday, July 30,2026 For Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For Quarter Ended June 30,2026.
2d - Board approved Q1 FY2026-27 standalone and consolidated results on July 30, 2026; unmodified review.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Jul - Announcement under Regulation 30 (LODR) - Analyst / Investor Meet- Intimation of Q1 Earnings call.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
Jul 2026TranscriptPPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
Jun 2023TranscriptPPTREC
-
Feb 2023TranscriptAI SummaryPPT
-
May 2022TranscriptPPT
-
Jan 2022Transcript PPT
-
Jul 2017TranscriptAI SummaryPPT
-
Jul 2016TranscriptAI SummaryPPT
-
Nov 2011TranscriptPPT
Business Profile[1]
Privi Speciality Chemicals Limited, formerly Fairchem Speciality Limited, is India’s largest manufacturer and exporter of aroma chemicals, holding a >20% global market share in ten products. The company specializes in manufacturing, supplying, and exporting bulk aroma and fragrance chemicals.[2]